Another advantage of future addition of a pTau measure to our plasma panel would be that our panel then reflects the complete ATN (amyloid, tauopathy, neurodegeneration) classification [3], wherein “A” would be our Abeta(1-42/1-40), “T” would be a pTau measure, and we would propose NfL or GFAP to measure “N.” This evidence concerns the gene GFAP and tauopathy.